1 terminated. 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Terminated 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) isatuximab 10 mg/kg - Platelet Refractoriness, Hematologic Malignancy | Early Phase 1 | Terminated | Firas El Chaer, MD | 3 | 2022-11-29 | 2024-07-31 |
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Site (1)
isatuximab (1)
United States (1)